3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Unknown
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Gastrointestinal
1
Breast
1
Conditions
Carcinoma, Non-Small-Cell Lung
4
Breast Neoplasms
4
Thyroid Cancer, Papillary
3
Sarcoma
3
Colonic Neoplasms
3
Central Nervous System Neoplasms
3
Carcinoma, Medullary
3
Wilms Tumor
2
Thyroid Neoplasms
2
Thyroid Diseases
2
Thoracic Neoplasms
2
Sarcoma, Ewing
2
Rhabdomyosarcoma
2
Rhabdoid Tumor
2
Respiratory Tract Neoplasms
2
Respiratory Tract Diseases
2
Osteosarcoma
2
Neuroectodermal Tumors, Primitive, Peripheral
2
Neuroblastoma
2
Neoplasms by Site
2
Neoplasms
2
Medulloblastoma
2
Lymphoma, Non-Hodgkin
2
Lung Neoplasms
2
Lung Diseases
2
Histiocytosis, Langerhans-Cell
2
Hepatoblastoma
2
Head and Neck Neoplasms
2
Glioma
2
Ependymoma
2
Interventions
Oxaliplatin
29
Fluorouracil
25
Leucovorin
20
Capecitabine
18
Irinotecan
17
Surveys and Questionnaires
16
Bevacizumab
14
Cisplatin
12
Blood Specimen Collection
11
Drug Therapy
10
Standard of Care
9
Nivolumab
9
Gemcitabine
9
Cetuximab
7
pembrolizumab
6
Specimen Handling
6
S 1 (combination)
6
Endoscopic Mucosal Resection
6
Cyclophosphamide
6
atezolizumab
5
Sunitinib
5
Radiotherapy
5
Folfox protocol
5
Educational Status
5
Docetaxel
5
fludarabine
4
aldesleukin
4
Radiosurgery
4
Pemetrexed
4
Magnetic Resonance Spectroscopy
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastrointestinal Neoplasms
×
selpercatinib
×
Gastrointestinal
×
Clear all
NCT04591431
2023-10-03
ROME
Fondazione per la Medicina Personalizzata
Phase 2
Unknown
400 enrolled